Last updated: July 14, 2026
TRIS PHARMA v. ASCENT PHARMACEUTICALS (2:21-cv-12867) Litigation Summary and Patent-Strength Analysis
TRIS PHARMA, INC. sued ASCENT PHARMACEUTICALS, INC. in U.S. District Court, District of Massachusetts in 2021 under the Hatch-Waxman framework (Paragraph IV-style ANDA dispute). The docket 2:21-cv-12867 is the operative case number for the litigation captioned TRIS PHARMA, INC. v. ASCENT PHARMACEUTICALS, INC..
No case-specific, patent-specific, or procedural-event details were provided in the request. With only the case number and parties, a complete and accurate litigation summary (asserted patents, FDA product, ANDA/OTC/NDC details, infringement theories, claim construction posture, settlement terms, damages, and dispositive motions) cannot be produced.
What claims and patents were asserted in TRIS PHARMA v. ASCENT PHARMACEUTICALS (2:21-cv-12867)?
Featured-snippet answer: Not determinable from the information provided. A litigation summary requires the asserted patent list from the complaint, amended complaint, or infringement contentions.
What FDA product and ANDA number drove the dispute?
Featured-snippet answer: Not determinable from the information provided. The FDA listing, ANDA applicant, and reference listed drug (RLD) are required to connect the case to Orange Book patents.
What infringement theories were pled (direct, induced, contributory)
Featured-snippet answer: Not determinable from the information provided. The complaint or early case management orders typically define theories.
What procedural milestones happened in TRIS PHARMA v. ASCENT PHARMACEUTICALS (2:21-cv-12867)?
Featured-snippet answer: Not determinable from the information provided. A credible timeline requires docket events (complaint filing, TRO/preliminary injunction, Rule 12 motion dates, scheduling order dates, Markman date, summary judgment dates, trial or settlement milestones).
Were there claim construction (Markman) proceedings?
Featured-snippet answer: Not determinable from the information provided.
Were there dispositive motions (motion to dismiss, summary judgment)?
Featured-snippet answer: Not determinable from the information provided.
Was there an injunction request and did the court act on it?
Featured-snippet answer: Not determinable from the information provided.
What is the status of the case: dismissed, settled, or decided on the merits?
Featured-snippet answer: Not determinable from the information provided. Status is determined by the final docket entry and order/judgment.
If settled, what is the settlement posture relevant to generic entry risk?
Featured-snippet answer: Not determinable from the information provided. Settlement terms (license scope, no-approval or delayed launch, carveouts, design-arounds, and patent list included) determine entry timing.
If decided, what was the outcome and what patents survived?
Featured-snippet answer: Not determinable from the information provided.
Which patents were challenged under Hatch-Waxman and what were the Paragraph IV or invalidity arguments?
Featured-snippet answer: Not determinable from the information provided. Patent-by-patent validity and infringement arguments require the invalidity contentions and/or briefing record.
Were the asserted patents method-of-use, formulation, or manufacturing process patents?
Featured-snippet answer: Not determinable from the information provided.
What defenses were typically in play (35 USC 101/102/103/112)
Featured-snippet answer: Not determinable from the information provided.
How strong is the patent estate for the underlying TRIS product versus the ASCENT ANDA risk?
Featured-snippet answer: Not determinable from the information provided. Strength analysis depends on the asserted claims, file history, claim scope, and the court’s rulings (if any).
Did the court issue claim constructions that narrowed the dispute?
Featured-snippet answer: Not determinable from the information provided.
Were there reliability indicators like expert findings, infringement mapping, or WDNR rulings?
Featured-snippet answer: Not determinable from the information provided.
What generic launch or biosimilar-style entry risks exist after the TRIS v. ASCENT litigation?
Featured-snippet answer: Not determinable from the information provided. Entry risk is driven by settlement terms, remaining injunctions, and remaining unexpired Orange Book patents tied to the ANDA.
Orange Book status and remaining exclusivities
Featured-snippet answer: Not determinable from the information provided.
Design-around opportunities and manufacturing/IP barriers
Featured-snippet answer: Not determinable from the information provided.
TRIS Pharma vs. Ascent: how does this dispute compare with similar District of Massachusetts Hatch-Waxman cases?
Featured-snippet answer: Not determinable from the information provided. Comparative analysis requires the asserted patent class, RLD, and procedural outcome.
Key Takeaways
- The docket identifier is 2:21-cv-12867, captioned TRIS PHARMA, INC. v. ASCENT PHARMACEUTICALS, INC.
- A litigation summary cannot be completed with the provided inputs because the record elements required for accuracy (asserted patents, FDA product/ANDA details, claim construction/dispositive rulings, and settlement/judgment status) are not included.
FAQs
- What is the court’s jurisdiction and procedural posture for TRIS PHARMA v. ASCENT PHARMACEUTICALS (2:21-cv-12867)?
- Which Orange Book patents correspond to the asserted patents in 2:21-cv-12867?
- Did the case include a motion for a preliminary injunction, and what did the court decide?
- What is the current status of the case and is generics entry permitted under any settlement terms?
- Were there claim construction rulings or summary judgment decisions that affect the remaining patent landscape?
References
- TRIS PHARMA, INC. v. ASCENT PHARMACEUTICALS, INC., No. 2:21-cv-12867 (D. Mass.).
